On this page
SMN1
survival of motor neuron 1, telomeric
The SMN1 gene encodes the survival motor neuron (SMN) protein, which is vital for the health and function of motor neurons and is primarily associated with spinal muscular atrophy. The SMN1 gene provides the blueprint for the survival motor neuron (SMN) protein.
SMN1 is located on the long (q) arm of chromosome 5, at band 5q13.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 5 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The SMN1 gene, or survival of motor neuron 1, telomeric, is crucial for producing the SMN protein. This protein is broadly distributed throughout the body, with the highest concentrations found within the spinal cord. The SMN protein is a key component of the SMN complex, which plays an essential role in maintaining motor neurons-nerve cells situated in the spinal cord and brainstem that send signals to skeletal muscles, enabling movement.
What the gene does
The SMN protein, produced from the SMN1 gene, is integral to the SMN complex. This complex has a significant function in the cellular processing of messenger RNA (mRNA) molecules, which act as genetic instructions for protein synthesis. Specifically, the SMN complex helps to assemble the cellular machinery necessary for the maturation of pre-mRNA into its final, functional form. Beyond mRNA processing, the SMN complex is also important for the development of dendrites and axons, which are specialised outgrowths of nerve cells that are critical for transmitting electrical impulses between neurons and from neurons to muscles. A similar gene, SMN2, also produces some SMN protein, but much of its product is a less stable, non-functional version.
Video: Genetics 101
Chromosome location
The SMN1 gene is located on the long arm of chromosome 5, specifically at position 5q13.2. This region contains genetic information essential for the production of the survival motor neuron protein.
Protein structure
The SMN protein consists of 294 amino acids and features several distinct functional regions and domains. The N-terminal portion includes disordered regions spanning amino acids 1-32, 59-88, and 156-222. An interaction region for GEMIN2 is located between amino acids 26-51. A key Tudor domain is found from amino acids 91-151, which overlaps with a region from 97-209 required for interaction with RPP20/POP7. Further along the protein, a P2 binding site for SNRPB is located between amino acids 240-267. Homooligomerization, where SMN proteins bind to each other, involves the region from amino acids 252-280. The C-terminal end, from amino acids 279-294, is required for interaction with SYNCRIP.
Key variants
Variants within the SMN1 gene can lead to changes in the SMN protein, potentially affecting its function or stability. These genetic alterations can include deletions, duplications, or single nucleotide changes. The impact of a specific variant on protein function can range from mild impairment to complete loss, influencing the severity of associated conditions.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.399_402del | p.Glu134fs | Pathogenic | ★★☆☆ | not provided |
c.469C>T | p.Gln157Ter | Pathogenic | ★★☆☆ | Werdnig-Hoffmann disease |
c.510_511del | p.Ser170fs | Pathogenic | ★★☆☆ | not provided |
c.549del | p.Lys184fs | Pathogenic | ★★☆☆ | Spinal muscular atrophy |
c.584del | p.Pro195fs | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.597dup | p.Met200fs | Pathogenic/Likely pathogenic | ★★☆☆ | Werdnig-Hoffmann disease |
c.796T>C | p.Ser266Pro | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.835-1G>A | - | Pathogenic/Likely pathogenic | ★★☆☆ | Spinal muscular atrophy |
c.835-2A>G | - | Pathogenic/Likely pathogenic | ★★☆☆ | Spinal muscular atrophy |
c.835G>C | p.Gly279Arg | Pathogenic/Likely pathogenic | ★★☆☆ | Spinal muscular atrophy |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the SMN1 gene are the primary cause of spinal muscular atrophy. This group of inherited conditions is characterised by a progressive loss of motor neurons, leading to muscle weakness and wasting (atrophy). Spinal muscular atrophy can manifest with varying degrees of severity and age of onset, leading to classifications such as SMA type II (Dubowitz), SMA type III (Kugelberg-Welander), and SMA type IV (adult-onset).
- Spinal muscular atrophy
- SMA type II (Dubowitz) Dedicated page coming soon
- SMA type III (Kugelberg-Welander) Dedicated page coming soon
- SMA type IV (adult-onset) Dedicated page coming soon
Inheritance pattern
Conditions caused by pathogenic SMN1 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
SMN1 is included on several NHS Genomic Medicine Service national test panels. These include panels for Arthrogryposis, Foetal anomalies, Hereditary neuropathy, Hereditary neuropathy or pain disorder, Paediatric motor neuronopathies, and for the diagnostic testing of Spinal muscular atrophy (R71).
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the function of the SMN1 gene?
The SMN1 gene provides instructions for making the survival motor neuron (SMN) protein. This protein is essential for the health and maintenance of motor neurons, which are nerve cells responsible for controlling muscle movement.
What condition is associated with the SMN1 gene?
Pathogenic variants in the SMN1 gene are primarily associated with spinal muscular atrophy (SMA). SMA is a genetic disorder characterised by progressive muscle weakness and wasting due to the loss of motor neurons.
How does the SMN1 gene relate to the SMN2 gene?
The SMN1 gene is almost identical to the SMN2 gene. While SMN1 produces the majority of functional SMN protein, SMN2 can produce a small amount of functional SMN protein, which can modify the severity of spinal muscular atrophy.
References
- Fuller HR, Gillingwater TH, Wishart TM. Commonality amid diversity: Multi-study proteomic identification of conserved disease mechanisms in spinal muscular atrophy. Neuromuscular disorders : NMD. 2016. PMID: 27460344
- Farrar MA, Kiernan MC. The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2015. PMID: 25413156
- Kolb SJ, Kissel JT. Spinal Muscular Atrophy. Neurologic clinics. 2015. PMID: 26515624
- Blauw HM, Barnes CP, van Vught PW. SMN1 gene duplications are associated with sporadic ALS. Neurology. 2012. PMID: 22323753
- Corcia P, Camu W, Praline J. The importance of the SMN genes in the genetics of sporadic ALS. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. 2009. PMID: 19922137
- Kolb SJ, Battle DJ, Dreyfuss G. Molecular functions of the SMN complex. Journal of child neurology. 2007. PMID: 17761654
- Cartegni L, Hastings ML, Calarco JA. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. American journal of human genetics. 2006. PMID: 16385450
- Corcia P, Camu W, Halimi JM. SMN1 gene, but not SMN2, is a risk factor for sporadic ALS. Neurology. 2006. PMID: 16931506
- Gubitz AK, Feng W, Dreyfuss G. The SMN complex. Experimental cell research. 2004. PMID: 15120993
- Prior TW, Swoboda KJ, Scott HD. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. American journal of medical genetics. Part A. 2004. PMID: 15378550